Total Payments
$123,056
2024 Payments
$15,696
Companies
10
Transactions
115
Medicare Patients
5,095
Medicare Billing
$496,341
Payment Breakdown by Category
Consulting$43,885 (35.7%)
Research$32,970 (26.8%)
Travel$28,751 (23.4%)
Other$14,776 (12.0%)
Food & Beverage$2,653 (2.2%)
Education$20.24 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $43,885 | 12 | 35.7% |
| Unspecified | $32,970 | 22 | 26.8% |
| Travel and Lodging | $28,751 | 24 | 23.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,276 | 13 | 11.6% |
| Food and Beverage | $2,653 | 42 | 2.2% |
| Honoraria | $500.00 | 1 | 0.4% |
| Education | $20.24 | 1 | 0.0% |
Payments by Type
General
$90,086
93 transactions
Research
$32,970
22 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $80,701 | 60 | $0 (2024) |
| Alnylam Pharmaceuticals Inc. | $36,576 | 34 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $3,488 | 3 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $1,685 | 12 | $0 (2024) |
| Akcea Therapeutics, Inc. | $500.00 | 1 | $0 (2019) |
| ABIOMED | $30.04 | 1 | $0 (2017) |
| Impulse Dynamics (USA) Inc. | $24.57 | 1 | $0 (2024) |
| CARDIVA MEDICAL, INC. | $22.00 | 1 | $0 (2019) |
| Medtronic Vascular, Inc. | $16.68 | 1 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $12.48 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $15,696 | 23 | PFIZER INC. ($12,591) |
| 2023 | $29,331 | 17 | Alnylam Pharmaceuticals Inc. ($17,570) |
| 2022 | $7,115 | 6 | PFIZER INC. ($3,985) |
| 2021 | $7,415 | 5 | PFIZER INC. ($4,470) |
| 2020 | $9,860 | 6 | PFIZER INC. ($6,350) |
| 2019 | $24,604 | 40 | PFIZER INC. ($13,253) |
| 2018 | $19,628 | 14 | PFIZER INC. ($19,611) |
| 2017 | $9,408 | 4 | PFIZER INC. ($9,378) |
All Payment Transactions
115 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | PFIZER INC. | VYNDAQEL (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: VYNDAQEL CLINICAL PUBLICATION PROGRAM • Category: CARDIOVASCULAR | ||||||
| 11/12/2024 | PFIZER INC. | VYNDAMAX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,200.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/31/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $237.90 | General |
| 09/19/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $188.00 | General |
| 09/19/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $163.52 | General |
| 09/19/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $163.52 | General |
| 09/19/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 09/19/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 09/19/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 09/19/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $30.00 | General |
| 09/19/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $30.00 | General |
| 09/19/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 09/19/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 09/19/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 08/30/2024 | PFIZER INC. | VYNDAQEL (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM • Category: CARDIOVASCULAR | ||||||
| 08/22/2024 | Impulse Dynamics (USA) Inc. | Optimizer (Device), Optimizer | Food and Beverage | Cash or cash equivalent | $24.57 | General |
| Category: Cardiovascular Device | ||||||
| 08/16/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $800.02 | General |
| 07/08/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $23.31 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/29/2024 | PFIZER INC. | VYNDAQEL (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM • Category: CARDIOVASCULAR | ||||||
| 05/26/2024 | PFIZER INC. | VYNDAQEL (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: VYNDAQEL CLINICAL PUBLICATION PROGRAM • Category: CARDIOVASCULAR | ||||||
| 02/28/2024 | PFIZER INC. | VYNDAQEL (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM • Category: CARDIOVASCULAR | ||||||
| 01/26/2024 | PFIZER INC. | VYNDAQEL (Drug) | — | In-kind items and services | $780.00 | Research |
| Study: TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM • Category: CARDIOVASCULAR | ||||||
| 01/19/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,395.00 | General |
| 12/15/2023 | PFIZER INC. | VYNDAQEL (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM • Category: CARDIOVASCULAR | ||||||
| 12/15/2023 | PFIZER INC. | VYNDAQEL (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM • Category: CARDIOVASCULAR | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TAFAMIDIS CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $14,800 | 10 |
| TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $13,250 | 9 |
| VYNDAQEL CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,140 | 2 |
| VYNDAMAX CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $780.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 1,241 | 1,850 | $506,697 | $110,683 |
| 2022 | 16 | 1,324 | 2,064 | $562,776 | $133,655 |
| 2021 | 15 | 1,381 | 2,106 | $615,049 | $147,268 |
| 2020 | 12 | 1,149 | 1,615 | $411,580 | $104,735 |
Total Patients
5,095
Total Services
7,635
Medicare Billing
$496,341
Procedure Codes
66
All Medicare Procedures & Services
66 procedure records from CMS Medicare Utilization — Page 2 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2022 | 12 | 48 | $5,040 | $2,242 | 44.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 17 | 17 | $6,780 | $2,183 | 32.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 23 | 23 | $4,669 | $2,021 | 43.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 13 | 13 | $4,750 | $1,709 | 36.0% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 186 | 260 | $7,800 | $1,627 | 20.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 14 | 23 | $3,243 | $1,370 | 42.2% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2022 | 21 | 22 | $15,928 | $1,311 | 8.2% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2022 | 14 | 14 | $13,818 | $774.76 | 5.6% |
| 93356 | Heart muscle strain imaging | Office | 2022 | 18 | 18 | $2,358 | $606.57 | 25.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 299 | 508 | $136,010 | $51,664 | 38.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 83 | 105 | $36,430 | $15,170 | 41.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 118 | 187 | $26,820 | $14,878 | 55.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 48 | 147 | $27,047 | $12,817 | 47.4% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Office | 2021 | 47 | 47 | $76,328 | $8,036 | 10.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 48 | 66 | $14,775 | $7,749 | 52.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 38 | 38 | $18,310 | $7,440 | 40.6% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 317 | 466 | $161,702 | $5,721 | 3.5% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2021 | 28 | 112 | $11,760 | $5,129 | 43.6% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 14 | 19 | $22,496 | $3,542 | 15.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 21 | 21 | $7,585 | $3,212 | 42.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 14 | 15 | $4,875 | $2,537 | 52.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 22 | 23 | $4,669 | $2,071 | 44.4% |
| 93015 | Exercise or drug-induced heart and blood vessel stress test with ekg monitoring, physician supervision, interpretation, and report | Office | 2021 | 31 | 31 | $30,597 | $1,723 | 5.6% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2021 | 175 | 242 | $7,260 | $1,640 | 22.6% |
| 93224 | Heart rhythm tracing, analysis, and interpretation of 48-hour ekg, includes recording, scanning analysis with report | Office | 2021 | 28 | 28 | $20,272 | $1,616 | 8.0% |
About Dr. Brian Drachman, MD
Dr. Brian Drachman, MD is a Cardiovascular Disease healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1801827597.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brian Drachman, MD has received a total of $123,056 in payments from pharmaceutical and medical device companies, with $15,696 received in 2024. These payments were reported across 115 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($43,885).
As a Medicare-enrolled provider, Drachman has provided services to 5,095 Medicare beneficiaries, totaling 7,635 services with total Medicare billing of $496,341. Data is available for 4 years (2020–2023), covering 66 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Philadelphia, PA
- Active Since 07/05/2006
- Last Updated 07/18/2018
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1801827597
Products in Payments
- VYNDAQEL (Drug) $39,328
- ONPATTRO (Drug) $16,211
- VYNDAMAX (Drug) $5,980
- TEGSEDI (Drug) $500.00
- Impella (Device) $30.04
- AMVUTTRA (Drug) $24.63
- Optimizer (Device) $24.57
- Vascular Closure Device (Device) $22.00
- HeartWare HVAD (Device) $16.68
- ELIQUIS (Drug) $12.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Philadelphia
Paul Forfia, Md, MD
Cardiovascular Disease — Payments: $1.4M
Cardiovascular Disease $1.4M
Quang Bui, Md, MD
Cardiovascular Disease — Payments: $1.0M
Cardiovascular Disease $1.0M
Anjali Vaidya, Md, MD
Cardiovascular Disease — Payments: $895,146
Cardiovascular Disease $895,146
Dean Karalis, Md, MD
Cardiovascular Disease — Payments: $760,521
Cardiovascular Disease $760,521
Ralph Verdino, Md, MD
Cardiovascular Disease — Payments: $683,076
Cardiovascular Disease $683,076
Francis Marchlinski, Md, MD
Cardiovascular Disease — Payments: $456,298
Cardiovascular Disease $456,298